Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients

Rita Paniccia, Emilia Antonucci, Niccolò Maggini, Marco Miranda, Anna Maria Gori, Rossella Marcucci, Betti Giusti, Daniela Balzi, Domenico Prisco, Rosanna Abbate

Research output: Contribution to journalArticlepeer-review

Abstract

Cardiovascular events are more frequent in high-risk coronary artery disease (CAD) patients on dual antiplatelet therapy with a residual platelet reactivity (RPR) than in those showing inhibition of ADP-inducible platelet activation. It is known that post-interventional RPR is a clinically important entity confirming it as a risk factor for thrombo-ischaemic events. Multiple electrode platelet aggregometry (MEA) on whole blood has been recently proposed as a rapid tool to evaluate RPR in high-risk CAD patients on clopidogrel therapy. It was the aim of this study to detect RPR in 801 high-risk CAD patients on dual antiplatelet therapy comparing MEA with the VerifyNow P2Y12 assay on whole blood and classical light transmission aggregation (LTA) on plateletrich plasma. ADP (10 μM) was employed as agonist for MEA and LTA. The prevalence of RPR was 20.6% by MEA, 16.1% by LTA and 30.8% by VerifyNow. MEA showed a significant correlation (rho=0.62, p

Original languageEnglish
Pages (from-to)287-292
Number of pages6
JournalThrombosis and Haemostasis
Volume104
Issue number2
DOIs
Publication statusPublished - Aug 2010

Keywords

  • Clopidogrel therapy
  • Light transmission aggregometry
  • Multiple electrode aggregometry
  • Point-of-care testing
  • Residual platelet reactivity

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients'. Together they form a unique fingerprint.

Cite this